Reply to A. Addeo and A. Bahl

J Clin Oncol. 2016 Feb 1;34(4):387-8. doi: 10.1200/JCO.2015.64.6562. Epub 2015 Nov 23.

Authors

Howard I Scher¹, Glenn Heller², Arturo Molina³, Thian Kheoh⁴, Johann S de Bono⁵

Affiliations

¹ Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY [email protected].
² Memorial Sloan Kettering Cancer Center, New York, NY.
³ Janssen Research & Development, Menlo Park, CA.
⁴ Janssen Research & Development, San Diego, CA.
⁵ The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom.

PMID: 26598756
DOI: 10.1200/JCO.2015.64.6562

No abstract available

Publication types

Letter
Comment

MeSH terms

Androstenes / therapeutic use*
Biomarkers, Tumor / analysis*
Humans
Male
Neoplastic Cells, Circulating / pathology*
Prostatic Neoplasms, Castration-Resistant / pathology*

Substances

Androstenes
Biomarkers, Tumor

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States